Conditional approval for Hansa’s kidney transplant drug by Selina McKee | Aug 27, 2020 | News | 0 Idefirix is an immunosuppressant that reduces the level of donor specific antibodies, thus enabling transplantation Read More
EMA accepts marketing authorisation applications for Idefirix and Xospata by Anna Smith | Mar 4, 2019 | News | 0 European regulators have accepted for review marketing authorisation applications for Hansa’s Idefirix and Astellas’ Xospata. Read More